Illumina MiSeq i100 System

The FDA is seeking to acquire one Illumina MiSeq i100 Whole Genome Sequencing System for the Irvine Medical Products Laboratory. The system must meet specific requirements, including the use of sequencing-by-synthesis next-generation sequencing technology, support for single-read and paired-end libraries, and a maximum read length of at least 2 × 300 base pairs. The contractor shall provide a minimum one-year manufacturer's warranty, operator training, and system familiarization for up to three end-users. The deliverables include the whole genome sequencing system and manufacturer warranty. The delivery location is the FDA/IRVLMP in Irvine, California. • The system must use sequencing-by-synthesis next-generation sequencing technology • The system must support single-read and paired-end libraries • The system must have an output range of up to 25 Gigabases • The system must have a maximum read length of at least 2 × 300 base pairs • The system must include onboard data collection and sequence alignment software • The system must include a monitor and control computer • The system must be a benchtop system not exceeding 16” × 18” × 26” (W×D×H)